Biltmore Family Office LLC purchased a new stake in DENTSPLY SIRONA Inc (NASDAQ:XRAY) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 5,400 shares of the medical instruments supplier’s stock, valued at approximately $356,000.
A number of other large investors have also bought and sold shares of the stock. BlackRock Inc. boosted its stake in DENTSPLY SIRONA by 0.7% during the fourth quarter. BlackRock Inc. now owns 14,169,813 shares of the medical instruments supplier’s stock valued at $932,797,000 after buying an additional 104,894 shares during the period. Generation Investment Management LLP boosted its stake in DENTSPLY SIRONA by 115.6% during the fourth quarter. Generation Investment Management LLP now owns 9,011,670 shares of the medical instruments supplier’s stock valued at $593,238,000 after buying an additional 4,831,112 shares during the period. Ruane Cunniff & Goldfarb Inc. boosted its stake in DENTSPLY SIRONA by 0.5% during the third quarter. Ruane Cunniff & Goldfarb Inc. now owns 8,890,655 shares of the medical instruments supplier’s stock valued at $531,750,000 after buying an additional 40,767 shares during the period. Clearbridge Investments LLC boosted its stake in DENTSPLY SIRONA by 5.1% during the fourth quarter. Clearbridge Investments LLC now owns 6,958,367 shares of the medical instruments supplier’s stock valued at $458,069,000 after buying an additional 340,634 shares during the period. Finally, Jackson Square Partners LLC lifted its stake in DENTSPLY SIRONA by 8.8% during the fourth quarter. Jackson Square Partners LLC now owns 6,891,530 shares of the medical instruments supplier’s stock worth $453,669,000 after purchasing an additional 556,624 shares during the last quarter. 96.80% of the stock is owned by institutional investors.
In other news, Director Eric Brandt sold 6,409 shares of the business’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $68.04, for a total value of $436,068.36. Following the completion of the sale, the director now owns 12,073 shares of the company’s stock, valued at approximately $821,446.92. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 1.99% of the company’s stock.
DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, March 1st. The medical instruments supplier reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.81 by $0.01. DENTSPLY SIRONA had a positive return on equity of 8.35% and a negative net margin of 39.39%. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the previous year, the company posted $0.67 EPS. DENTSPLY SIRONA’s revenue for the quarter was up 9.5% on a year-over-year basis. analysts expect that DENTSPLY SIRONA Inc will post 2.74 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 13th. Stockholders of record on Thursday, March 29th will be paid a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date of this dividend is Wednesday, March 28th. DENTSPLY SIRONA’s dividend payout ratio (DPR) is presently -5.09%.
Several equities research analysts have issued reports on the company. HC Wainwright lowered DENTSPLY SIRONA from a “buy” rating to a “neutral” rating and set a $68.00 price target for the company. in a research note on Thursday, November 30th. JPMorgan Chase & Co. dropped their price target on DENTSPLY SIRONA from $75.00 to $70.00 and set an “overweight” rating for the company in a research note on Monday, March 5th. Barrington Research reaffirmed an “outperform” rating and set a $70.00 price target (down previously from $73.00) on shares of DENTSPLY SIRONA in a research note on Monday, March 5th. BidaskClub lowered DENTSPLY SIRONA from a “sell” rating to a “strong sell” rating in a research note on Wednesday, February 28th. Finally, Credit Suisse Group dropped their price target on DENTSPLY SIRONA from $73.00 to $69.00 and set an “outperform” rating for the company in a research note on Friday, March 2nd. Three analysts have rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $67.43.
ILLEGAL ACTIVITY NOTICE: “Biltmore Family Office LLC Purchases Shares of 5,400 DENTSPLY SIRONA Inc (XRAY)” was originally published by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://weekherald.com/2018/03/16/biltmore-family-office-llc-purchases-shares-of-5400-dentsply-sirona-inc-xray.html.
DENTSPLY SIRONA Profile
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.